Timeline
Valirx
ValiRx ends University of Dundee drug discovery collaboration after technology fails to meet licensing threshold
ValiRx shares tumbled after Stingray evaluation ends
ValiRx exercises RNA option after evaluation finishes four months early
ValiRx's Cytolytix secures European patent for nanoparticle delivery
ValiRx raises up to £1.155m to fund McGill in‑licence, Cytolytix preclinical work and animal‑health expansion
More in Biotech
GENinCode genetic test cuts cardiac risk in Catalonia pilot
A real-world pilot by Catalonia's health service found GENinCode's CARDIO inCode-Score reclassified risk in over 40% of moderate-risk patients and drove measurable improvements in cholesterol and smoking cessation.